HUTCHMED (00013) rose more than 3% during the trading session. At the time of writing, the stock was up 2.39%, trading at HKD 23.98, with a turnover of HKD 77.411 million.

According to an announcement on HUTCHMED's official WeChat account on January 14th, the company announced that the results of the SACHI Phase III study have been published in The Lancet. SACHI is a Phase III study evaluating the combination therapy of savolitinib (Orpathys®) and osimertinib (Tagrisso®) for the treatment of patients with EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer who have experienced disease progression after first-line EGFR tyrosine kinase inhibitor therapy and have MET amplification.

Savolitinib is described as a potent, highly selective oral MET TKI, co-developed by AstraZeneca and HUTCHMED and commercialized by AstraZeneca. Osimertinib is an irreversible, third-generation EGFR TKI. Based on the data from the SACHI study, the combination therapy of savolitinib and osimertinib was approved in China in June 2025.